MindMed to Participate in the Jefferies Global Healthcare Conference
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Jefferies Global Healthcare Conference in New York from June 8-10, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Jefferies Global Healthcare Conference in New York from June 8-10, 2022. CEO Robert Barrow will present on June 10, 2022, at 12:45 p.m. ET. The event includes an in-person presentation and one-on-one investor meetings. A webcast of the presentation will be available at this link, with a replay for 90 days on MindMed's website. MindMed focuses on developing treatments for brain health disorders.
Details
News Market Reaction – MNMD
The recorded move for MNMD in the trading session of this news was +3.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY from June 8-10, 2022.
Jefferies Global Healthcare Conference
Format: In-person presentation and scheduled one-on-one investor meetings
Presentation Date: Friday, June 10, 2022
Time: 12:45 p.m. ET
Webcast Link: https://wsw.com/webcast/jeff240/mnmd/1841100
A replay of the webcast will be available in the "News & Media" section of MindMed's website for 90 days following each of the presentations.
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-the-jefferies-global-healthcare-conference-301558892.html
SOURCE Mind Medicine (MindMed) Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.